Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989698 | 0.84 | PPARA (0.54) | LMNAALDH1A1PPARAABCB11CYP1A2 | |
| SCHEMBL23605988 | 0.84 | L3MBTL1 (0.49) | LMNATRPM8ALDH1A1L3MBTL1PPARA | |
| SCHEMBL23605972 | 0.81 | MAPT (0.42) | LMNATRPM8ALDH1A1L3MBTL1PPARA | |
| SCHEMBL23605971 | 0.79 | ABCB11 (0.46) | LMNATRPM8ALDH1A1L3MBTL1PPARA | |
| SCHEMBL12836589 | 0.77 | PTPN7 (0.45) | ALDH1A1PPARACYP1A2PPARDPPARG | |
| SCHEMBL27493501 | 0.77 | PARP10 (0.38) | PARP10LMNAWDR5TRPM8ALDH1A1 | |
| SCHEMBL23605978 | 0.77 | MAPT (0.40) | LMNATRPM8ALDH1A1L3MBTL1PPARA | |
| SCHEMBL27559203 | 0.76 | ADORA3 (0.41) | PARP10LMNAWDR5TRPM8L3MBTL1 | |
| SCHEMBL27559202 | 0.76 | ADORA3 (0.41) | PARP10LMNAWDR5TRPM8L3MBTL1 | |
| SCHEMBL3948925 | 0.76 | PPARA (0.47) | PARP10LMNAWDR5TRPM8PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-2268140-B1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, CTSA | PARP10 1119/4885LMNA 680/4885WDR5 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.